0
Transplantation |

Addition of Rapamycin to the Immunosuppressant Regimen Improves Airway Patency in Lung Transplant Patients With Refractory Bronchial Stenosis

Irina Timofte, MD; Maria Crespo, MD; Christian Bermudez, MD; Jonathan D'Cunha, MD; Jay Bhama, MD; Norihisa Shigemura, MD; Bruce Johnson, MD
Author and Funding Information

UPMC, Pittsburgh, PA


Chest. 2013;144(4_MeetingAbstracts):1014A. doi:10.1378/chest.1703797
Text Size: A A A
Published online

Abstract

SESSION TITLE: Lung Transplantation Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Airway complications such as bronchial stenosis can be a significant cause of morbidity and mortality after lung transplantation. These patients often require multiple interventional bronchoscopic procedures. Since sirolimus has well recognized antiproliferative and immunosuppressive properties, we hypothesized that adding rapamycin to the immunosuppressant regimen of lung transplant recipients who required multiple bronchoscopic intervention for bronchial stenosis would facilitate achieving and maintaining airway patency.

METHODS: We retrospectively reviewed the charts of all lung transplant patients who were started on rapamycin after development of severe bronchial stenosis that required multiple consecutive interventions including balloon bronchoplasty, laser photoresection, endobronchial brachytherapy, and bronchial stents placement.

RESULTS: A total of 10 patients who underwent single or double lung transplantation from 2000 to 2012 were included. All patient had severe airway occlusion (80-100% reduction in cross sectional area) requiring multiple interventional bronchoscopic procedures prior to initiating rapamycin. After adding rapamycin, 8 of 10 patients achieved airway patency within 3 months and 7 of 10 had a significant response in the first month. Additionally, 5 of 7 patients who continued Rapa as part of their immunosuppressive regiment for more than 6 month did not require other subsequent interventional bronchoscopic procedures.

CONCLUSIONS: Airway complications have been mainly attributed to ischemia of the donor bronchus during the immediate post-transplant period. Primary graft dysfunction and especially grade 3-4 ischemia-reperfusion injury( Herrera clasification) is the main risk factors for airway complications. Rapamycin represents a promising option for lung transplant patients with severe airway stenosis.

CLINICAL IMPLICATIONS: The presence of severe persistent IRI should prompt starting Rapamycin early in the first 4-6 month after transplant.

DISCLOSURE: The following authors have nothing to disclose: Irina Timofte, Maria Crespo, Christian Bermudez, Jonathan D'Cunha, Jay Bhama, Norihisa Shigemura, Bruce Johnson

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543